Non-cystic fibrosis bronchiectasis in children and adolescents: Neglected and emerging issues

Marco Poeta1, Marco Maglione1, Melissa Borrelli1

  • 1Department of Translational Medical Sciences, Section of Pediatrics, Federico II University, Naples, Italy.

Insights

Pediatric non-cystic fibrosis (CF) bronchiectasis management is reviewed, focusing on novel assessment techniques and treatment advances. A new diagnostic algorithm is proposed to aid clinicians in managing this complex pediatric lung disease.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine

Background:

  • Pediatric non-cystic fibrosis (CF) bronchiectasis presents with airway inflammation and mucus issues, often leading to recurrent infections and cough.
  • Current management guidelines largely rely on expert opinion or extrapolation from CF practices.
  • There is a need for evidence-based strategies tailored to non-CF bronchiectasis in children.

Purpose of the Study:

  • To review current knowledge and address open questions in managing pediatric non-CF bronchiectasis.
  • To explore the role of technological advancements in lung disease assessment.
  • To summarize recent developments in disease prevention and treatment, and propose a diagnostic algorithm.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of novel chest imaging techniques and pulmonary function tests.
  • Synthesis of information on disease prevention, treatment, and diagnostic approaches.

Main Results:

  • Technological advances offer new possibilities for assessing lung disease in pediatric non-CF bronchiectasis.
  • Novelties in prevention and treatment strategies are emerging.
  • A proposed diagnostic algorithm can assist physicians in clinical decision-making.

Conclusions:

  • Further research with larger cohorts and longer trials is crucial.
  • Identifying new clinical and laboratory endpoints is needed to understand disease progression.
  • Evidence-based management strategies are essential for improving outcomes in pediatric non-CF bronchiectasis.

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
422
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
673
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
2.9K